TScan Therapeutics 的股价在获得 3000 万美元的交易后飙升，将其现金跑道延长至 2027 年。 TScan Therapeutics' stock surged after securing a $30 million deal, extending its cash runway to 2027.

在与Lynx1资本管理有限公司达成3 000万美元的融资协议后,TSCAN治疗公司股票在市场前上涨了16.8%。 TScan Therapeutics' stock rose 16.8% premarket after agreeing to a $30 million financing deal with Lynx1 Capital Management LP. 这笔交易以37%的溢价计价,涉及以预先供资的授权书的形式出售750万股共同股票。 The deal, priced at a 37% premium, involves selling up to 7.5 million shares of common stock in the form of pre-funded warrants. 这项筹资定于2024年12月27日结束,将把TSCAN的现金资源扩大到2027年,以支持其为癌症病人发展TCR-T细胞疗法的任务。 This financing, set to close by December 27, 2024, will extend TScan's cash resources into 2027, supporting its mission to develop TCR-T cell therapies for cancer patients.